Complete tumor response following intratumoral 32P BioSilicon on human hepatocellular and pancreatic carcinoma xenografts in nude mice

Clinical Cancer Research

Volumn 11, Issue 20, 2005, Pages 7532-7537

  Zhang, Kai ^a   Loong, Susan L E ^b   Connor, Steve ^c   Yu, Sidney W K ^a   Tan, Soo Yong ^a   Ng, Robert T H ^a   Lee, Khai Mun ^b   Canham, Leigh ^c   Chow, Pierce K H ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c pSiMedica Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHORUS 32; SILICON;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEVICE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT OUTCOME; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; BRACHYTHERAPY; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; PHOSPHORUS RADIOISOTOPES; SILICON; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 27144491930     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0400     Document Type: Article

References (35)

1. Bakemeier R, Qazi R. Basic concepts of cancer chemotherapy and principles of chemotherapy. In: Rubin P, editor. Clinical oncology: a multidisciplinary approach for physicians and students. Philadelphia: Saunders; 2001. p. 146-59.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Venook AP. Hepatocellular carcinoma, Curr Treat Options Oncol 2000;1:107-15.
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:362907-17.
5. Oon CJ, Okuda K, Pang R. Primary hepatocellular carcinoma in the Asian Pacific region. Ann Acad Med Singapore 1980;9:990-2.
6. Wang TL, Yap IL, Tan YO. Hepatocellular carcinoma-a case series of 104 patients. Ann Acad Med Singapore 1991;20:2015-8.
7. Johnson PJ. Hepatocellular carcinoma: is current therapy really altering outcome? Gut 2002;51:5159-62.
8. Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004;40:40474-84.
9. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:5618-28.
10. Pawarode A, Tangkijvanich P, Voravud N. Outcomes of primary hepatocellular carcinoma treatment: an 8-year experience with 368 patients in Thailand. J Gastroenterol Hepatol 2000;15:1560-4.
11. Chow PK, Tai BC, Tan CK, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 2002;36:36221-6.
12. Haller DG. Future directions in the treatment of pancreatic cancer. Semin Oncol 2002;29:31-9.
13. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreatico-duodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221:22121-31.
14. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981;48:48705-10.
15. Westlin JE, Andersson-Forsman C, Garske U, Linne T, Aas M, Glimelius B. Objective responses after fractionated infusional brachytherapy of unresectable pancreatic adenocarcinomas. Cancer 1997;80:2743-8.
16. Minsky BD, Hilaris B, Fuks Z. The role of radiation therapy in the control of pain from pancreatic carcinoma. J Pain Symptom Manage 1988;3:399-205.
17. McCready VR, Comes P. The potential of intratumoural unsealed radioactive source therapy. Eur J Nucl Med 2001;28:2867-9.
18. Bomford CK, Kunkler IH. Radiation physics, therapy and oncology. In Walter & Miller's Textbook of Radiotherapy. 6th ed. New York: Churchill Livingstone; 2002. p. 246.
19. Order SE, Siegel JA, Principato R, Zerger LE, Johnson E, Lang D. Selective tumor irradiation by infusional brachytherapy in nonresectable pancreatic cancer: a phase I study. Int J Radiat Oncol Biol Phys 1996;36:1117-26.
20. Zhang DS, Liu L, Jin LD, Wan ML, Li OH. Effect of phosphorus-32 glass microspheres on human hepatocellular carcinoma in nude mice. World J Gastroenterol 2004;10:10551-4.
21. Canham LT. Bioactive silicon structure fabrication through nanoetching techniques. Adv Mater 1995;7:7033-5.
22. Canham LT In: Properties of porous silicon. London: IEE Press: 1997. p. 405.
23. Chin V, Collins BE, Sailor MJ, Bhatia SN. Compatibility of primary hepatocytes with oxidized nanoporous silicon. Adv Mater 2001;13:13877-80.
24. Rosengren A, Wallman L, Bengtsson M, Laurell T, Danielson N, Bjursten LM. Tissue reactions to porous silicon: a comparative biomaterial study. Phys Stat Solid (A) 2002;182:527-31.
25. Moxon KA, Kalkhoran NM, Market M, Sambito MA, McKenzie JL, Webster JT. Nanostructured surface modification of ceramic-based microelectrodes to enhance biocompatibility for a direct brain-machine interface. IEEE Trans Biomed Eng 2004;51:5181-9.
26. Shlinak IS. Neutron transmutation doping in semiconductors: science and applications. Phys Solid State 1999;41:716-9.
27. Wilkowski R, Thoma M, Schauer R, Wagner A, Heinemann V. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg 2004;28:28011-8.
28. Liu L, Jiang Z, Teng GJ, et al. Clinical and experimental study on regional administration of phosphorus 32 glass microspheres in treating hepatic carcinoma. World J Gastroenterol 1999;5:492-505.
29. Lin WY, Tsai SC, Hsieh JF, Wang ST. Effects of 90Y-microspheres on liver tumors: comparison of intratumoral injection method and intra-arterial injection method. J Nucl Med 2000;41:41892-7.
30. Chen SD, Hsieh JF, Tsai SC, Lin WY, Cheng KY, Wang SJ. Intra-tumoural injection of 90Y microspheres into an animal model of hepatoma. Nucl Med Commun 2001;22:2221-5.
31. Tian JH, Xu BX, Zhang JM, Dong BW, Liang P, Wang XD. Ultrasound-guided internal radiotherapy using yttrium-90-glass microspheres for liver malignancies. J Nucl Med 1996;37:3758-63.
32. Firusian N, Dempke W. An early phase II study of intratumoral P-32 chromic phosphate injection therapy for patients with refractory solid tumors and solitary metastases. Cancer 1999;85:8580-7.
33. DeNittis AS, Stambaugh MD, Lang P, et al. Complete remission of nonresectable pancreatic cancer after infusional colloidal phosphorus-32 brachytherapy, external beam radiation therapy, and 5-fluorouracil: a preliminary report. Am J Clin Oncol 1999;22:2255-60.
34. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160:160227-30.
35. El-Serag HB, Davila JA, Peterson NJ, Mcglynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:13917-23.